Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Synopsys, Inc. (SNPS) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

Synopsys, Inc.Trade
DENTSPLY SIRONA IncTrade

Price performance (Past 24H)

Key statistics

Synopsys, Inc. vs DENTSPLY SIRONA Inc — how do they compare? Synopsys, Inc. trades at $393.94 (market cap $75.13B), while DENTSPLY SIRONA Inc trades at $10.68 (market cap $2.19B). The key difference: Synopsys, Inc. is far larger — about 34.3× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.

SNPSXRAY
Market Cap
$75.13B$2.19B
Sector
TechnologyHealth
52-Week High
$534.56$14.68
52-Week Low
$372.33$9.64
Enterprise Value
$82.36B$4.26B
Dividend Yield
5.04%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Synopsys, Inc.

Synopsys (SNPS) trades at $392.03, down 0.46% on the day, with a bearish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, including Q2 2026 EPS of $3.91 versus $3.67 expected. Revenue growth remains strong, with fiscal 2025 revenue reaching $7.05 billion, though net income margin compressed to 11.43% in 2026. Analyst consensus is overwhelmingly bullish with a $541.88 price target, representing significant upside potential.

The outlook for SNPS is positive based on fundamental strength and Wall Street optimism, but risks include high valuation multiples (P/E of 68.42), competitive pressures in semiconductor software, and integration challenges from the Ansys acquisition. The stock's near-term performance will hinge on Q3 2026 earnings results and continued execution in the expanding AI-driven chip design market.

DENTSPLY SIRONA Inc

XRAY trades at $10.99, down 3.43% on the day, reflecting ongoing challenges amid a bearish technical signal. The company reported a Q2 2026 earnings beat but faces declining revenue and negative profitability, with a net income margin of -14.99%. Cash flow trends show volatility, and the debt-to-asset ratio has worsened to 42.88% in 2025. Recent news highlights margin pressure and a class-action lawsuit inquiry, clouding the near-term outlook despite some institutional buying interest.

The investment outlook is cautious. While the stock trades below the consensus price target of $12.50, persistent net losses, high debt, and competitive pressures pose significant risks. Analyst sentiment is mixed with a 'Hold' consensus, suggesting limited upside until the company demonstrates sustained operational improvement and revenue stabilization.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Synopsys, Inc.

Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.

Read more on SNPS

About DENTSPLY SIRONA Inc

Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters

Read more on XRAY